Form 4: Supernus Pharmaceuticals Director, Bethany Sensenig, Reports Acquisition of 5,369 Common Stock Units
SEC Form 4 Filing
Director Bethany Sensenig reports acquisition of 5,369 shares of Supernus Pharmaceuticals common stock through the vesting of restricted stock units.
Summary
- On February 22, 2025, Bethany Sensenig, a director of Supernus Pharmaceuticals, acquired 5,369 shares of common stock.
- This acquisition resulted from the vesting and settlement of restricted stock units (RSUs).
- Each RSU represents the right to receive one share of Supernus common stock upon vesting.
- The RSUs vested on February 22, 2025, and were settled in common stock.
- Following the transaction, Sensenig beneficially owns 5,369 shares of Supernus common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.
Key Dates
| Date | Description |
|---|---|
| 02/22/2025 | Date of transaction: Acquisition of common stock through vesting of restricted stock units. |
| 02/24/2025 | Date of signature on the Form 4 filing. |
Keywords
Supernus Pharmaceuticals, Form 4, SEC Filing, Beneficial Ownership, Director, Bethany Sensenig, Common Stock, Restricted Stock Units, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.